Antibody Developability Analysis
Evaluating the developability of therapeutic drug candidates early can help circumvent potential issues in late-stage development. These evaluations include the drug candidate’s biophysical and chemical properties assessment. At Curia, in silico predictive tools and a series of fast & small-scale assessments are employed to serve as additional selection criteria for better and safe therapeutic leads.
Curia offers three developability
assessment packages:
Developability Package 1
- In silico sequence liability analysis
- In silico immunogenicity analysis
- Turnaround time: 1 week
Developability Package 2
- Polyspecificity assessment
- Integrity and stability assessment
- Turnaround time: 2-3 weeks
Developability Package 3
- Buffer exchange
- Forced degradation
- Integrity and stability assessment
- Additional stress conditions
Key Highlights
Developability Assessment Services
Curia’s dedicated facility in Hayward for upstream and downstream process development, research cell bank (RCB) generation, and GMP manufacturing of analyte specific reagents.
